A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer

Tanyifor M. Tohnya, Sylvia S.W. Ng, William L. Dahut, John J. Wright, Philip M. Arlen, James L. Gulley, Catherine Parker, Jerome Zeldis, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences